Ligand Pharmaceuticals Incorporated (LGND)
LGND trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/886163/000088616326000006/0000886163-26-000006-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | LGND on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0000886163 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $268.1M |
| Net income | $124.5M |
| Operating income | $41.0M |
| Net margin | 46.4% |
| Operating margin | 15.3% |
| Revenue growth | +60.4% |
| Cash | $174.9M |
| Total assets | $1.6B |
| P/E (computed) | 48.5× |
| P/S (computed) | 22.5× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-10-30 |
| Cash and burn | $56.0M cash; operating cash flow $22.8M a quarter. | Report 2026-09-30 |
| Shares outstanding | 20,002,986 (2026-10-27); 19,681,720 a year earlier; 17,435,958 three years earlier. | Cover page 2026-10-27 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-02-27 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, San Diego, California, United States | PCAOB Form AP 2026-03-13 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $33.3M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $78.7M | -$28.5M | -$27.6M | $56.0M | $1.1B | $253.8M | 10-Q 2026-10-30 |
| Q2 2026 2026-06-30 | $63.7M | $48.5M | $24.0M | $1.0B | $1.1B | $290.5M | 10-Q 2026-08-07 |
| Q1 2026 2026-03-31 | $51.7M | -$13.3M | $48.7M | $115.1M | No debt tags | $274.5M | 10-Q 2026-05-08 |
| Q4 2025 2025-12-31 | $59.7M | $44.8M | $45.9M | $174.9M | No debt tags | $268.1M | 10-K 2026-02-27 |
| Q3 2025 2025-09-30 | $115.5M | $117.3M | $13.1M | $139.4M | No debt tags | $251.2M | 10-Q 2026-10-30 |
| Q2 2025 2025-06-30 | $47.6M | $4.8M | $15.8M | $67.7M | No debt tags | $187.6M | 10-Q 2026-08-07 |
| Q1 2025 2025-03-31 | $45.3M | -$42.5M | -$25.4M | $48.0M | No debt tags | $181.5M | 10-Q 2026-05-08 |
| Q4 2024 2024-12-31 | $42.8M | -$31.1M | $28.5M | $72.3M | No debt tags | $167.1M | 10-K 2026-02-27 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3ASR | 2026-02-27 |
| Latest annual report | 10-K | 2026-02-27 |
| Latest quarterly / interim | 10-Q | 2026-10-30 |
| Latest current report | 8-K | 2026-10-29 |
| Latest proxy | DEFA14A | 2026-05-18 |
Source: SEC EDGAR submissions feed, 1,003 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +0.8% |
| 1 month | +1.7% |
| 3 months | +6.9% |
| Year to date | +63.3% |
| 1 year | +53.4% |
| From 52-week high | -4.3% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| GRFS | Grifols S.A. | $8.73 | +0.46% | $6.0B |
| SUPN | Supernus Inc. | $28.83 | -2.99% | $6.0B |
| MIRM | Mirum Pharmaceuticals Inc. | $91.58 | -2.56% | $6.0B |
| ARWR | Arrowhead Pharmaceuticals Inc. | $44.21 | -7.47% | $6.2B |
| BLTE | Belite Bio Inc | $162.56 | -1.09% | $6.5B |
| MANE | Veradermics Incorporated | $128.05 | -1.24% | $5.4B |
| ERAS | Erasca Inc. | $15.11 | -3.51% | $5.3B |
| PTCT | PTC Therapeutics Inc. | $60.97 | -3.97% | $5.1B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier